252 related articles for article (PubMed ID: 20671225)
1. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
3. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
4. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
5. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
Daina E; Cravedi P; Alpa M; Roccatello D; Gamba S; Perna A; Gaspari F; Remuzzi G; Ruggenenti P
Nephron; 2015; 130(1):13-20. PubMed ID: 25895746
[TBL] [Abstract][Full Text] [Related]
6. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Slagman MC; Waanders F; Hemmelder MH; Woittiez AJ; Janssen WM; Lambers Heerspink HJ; Navis G; Laverman GD;
BMJ; 2011 Jul; 343():d4366. PubMed ID: 21791491
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
8. [Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Zhang DY; Yang YL; Chen WD; Huang YY; Li LH; Wang YW; Zhu XJ; Xu HH; Yang LC
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Dec; 19(12):762-3. PubMed ID: 18093443
[No Abstract] [Full Text] [Related]
9. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H
Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
[TBL] [Abstract][Full Text] [Related]
12. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
15. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P; Cortinovis M; Parvanova A; Trillini M; Iliev IP; Bossi AC; Belviso A; Aparicio MC; Trevisan R; Rota S; Perna A; Peracchi T; Rubis N; Martinetti D; Prandini S; Gaspari F; Carrara F; De Cosmo S; Tonolo G; Mangili R; Remuzzi G;
PLoS Med; 2021 Jul; 18(7):e1003691. PubMed ID: 34260595
[TBL] [Abstract][Full Text] [Related]
16. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
18. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
19. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
20. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
